|
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
- Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Tolebrutinib is an oral, brain-penetrant, and bioactive BTK inhibitor intended to target disease-associated microglia and B cells within the CNS in addition to their counterparts in the periphery
- Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease . . .
Targeted DNA Methylation Using Modified DNA Probes: A Potential Therapeutic Tool for Depression and Stress-Related Disorders, International Journal of Molecular Sciences, 26, 12, (5643), (2025
- Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
A total of 1721 patients (1680 adults and 41 adolescents) underwent randomization and received brensocatib or placebo The annualized rate of pulmonary exacerbations was 1 02 in the 10-mg
- VITT-like Monoclonal Gammopathy of Thrombotic Significance
Anti‐ PF4 mediated thrombocytopenia and thrombosis associated with acute cytomegalovirus infection displays both HIT ‐like and VITT ‐like characteristics , British Journal of Haematology
- First-Line Camizestrant for Emerging - The New England Journal of Medicine
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
|
|
|